肿瘤患者活检引导中CT与PET/CT的比较
前瞻性评估323例患者,181例接受FDG PET/CT引导活检(共188次),142例接受CT引导活检(共146次)。PET/CT组组织学确诊成功率96.8%,CT组93.8%,无显著差异(p=0.19);并发症率分别为12.7%和9.5%,亦无显著差异(p=0.26)。
要点
- PET/CT引导活检技术可行,尤其适用于CT上无对应病灶的FDG高摄取灶。
- PET/CT组与CT组在获取诊断性标本的能力上无显著差异(p=0.19)。
- 两组并发症率无显著差异(12.7% vs 9.5%,p=0.26)。
核心结论
- PET/CT引导活检是疑似恶性肿瘤诊断工作中可行且准确的方法。
- 本前瞻性大样本分析显示PET/CT作为活检引导影像方法具有可行性和优势,尤其当FDG高摄取灶在CT扫描上无对应病灶时。
- PET/CT与CT引导在获取诊断性标本的能力或并发症率方面无显著差异。
研究设计与样本
- 前瞻性评估323例患者,其中181例接受FDG PET/CT引导活检(共188次活检),142例接受CT引导活检(共146次活检)。
- 活检使用同一台PET/CT扫描仪并配备透视成像系统。
- 评估两组的技术可行性、临床成功率和并发症率。
主要发现
- PET/CT引导组188次活检中182次(96.8%)成功获得结论性组织样本,CT引导组146次中137次(93.8%)成功。
- PET/CT引导组188次中6次(3.1%)结果不确定,CT引导组146次中9次(6.1%)结果不确定(p=0.19)。
- 因组织学结果不确定,PET/CT引导组188个病灶中4个(2.1%)重新活检,CT引导组146个病灶中3个(2.0%)重新活检。
- PET/CT引导组188个病灶中142个(75.5%)为恶性、40个(21.2%)为良性;CT引导组146个病灶中89个(60.9%)为恶性、48个(32.8%)为良性(p分别为0.004和0.01)。
- 组织学诊断为良性病变的患者在至少6个月随访中无疾病复发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare FDG PET/CT and CT for the guidance of percutaneous biopsies with histological confirmation of lesions. METHODS: We prospectively evaluated 323 patients of whom 181 underwent FDG PET/CT-guided biopsy (total 188 biopsies) and 142 underwent CT-guided biopsy (total 146 biopsies). Biopsies were performed using the same PET/CT scanner with a fluoroscopic imaging system. Technical feasibility, clinical success and complication rates in the two groups were evaluated. RESULTS: Of the 188 biopsies with PET/CT guidance, 182 (96.8%) were successful with conclusive tissue samples obtained and of the 146 biopsies with CT guidance, 137 (93.8%) were successful. Therefore, 6 of 188 biopsies (3.1%) with PET/CT guidance and 9 of 146 (6.1%) with CT guidance were inconclusive (p = 0.19). Due to inconclusive histological results, 4 of the 188 lesions (2.1%) were rebiopsied with PET/CT guidance and 3 of 146 lesions (2.0%) were rebiopsied with CT guidance. Histology demonstrated that 142 of 188 lesions (75.5%) were malignant, and 40 (21.2%) were benign in the PET/CT-guided group, while 89 of 146 lesions (60.9%) were malignant and 48 (32.8%) were benign in the CT-guided group (p = 0.004 and 0.01, respectively). Patients with a histological diagnosis of benign lesion had no recurrence of disease with a minimum of 6 months follow-up. Of the 188 PET/CT-guided biopsies, 6 (3.1%) were repeat biopsies due to a previous nondiagnostic CT-guided biopsy performed in a different diagnostic centre. The interval between the two biopsies was less than a month in all cases. Histology revealed five malignant lesions and one benign lesion among these. The complication rate in the PET/CT-guided biopsy group was 12.7% (24 of 188), while in the CT-guided group, was 9.5% (14 of 146, p = 0.26). Therefore, there was no significant difference in complication rates between PET/CT and CT guidance. CONCLUSION: PET/CT-guided biopsy is already known to be a feasible and accurate method in the diagnostic work-up of suspected malignant lesions. This prospective analysis of a large number of patients demonstrated the feasibility and advantages of using PET/CT as the imaging method of choice for biopsy guidance, especially where FDG-avid foci do not show corresponding lesions on the CT scan. There were no significant differences in the ability to obtain a diagnostic specimen or in the complication rates between PET/CT and CT guidance.
引用
- Cerci JJ, Tabacchi E, Bogoni M, et al. Comparison of CT and PET/CT for biopsy guidance in oncological patients. Eur J Nucl Med Mol Imaging. 2017. PMID: 28364161. doi:10.1007/s00259-017-3658-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。